Kyverna Therapeutics, Inc.
HealthcareNASDAQ:KYTX · NASDAQ Global Select
+$0.19 today
Vol 0.65M · Avg 0.93M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-69.4%
avg -49.0%
ROIC
-65.0%
avg -62.5%
ROA
-54.9%
avg -50.2%
Analysis
ROA is currently the strongest return metric at -54.9% versus its period average of -50.2%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Warner Biddle | Chief Executive Officer & Director | $1.27M | — | 59 | $350,000.00 | 0.80% |
Naji Gehchan | Chief Medical & Development Officer | $975,073.00 | — | 44 | $18,000.00 | 0.04% |
Mayo Pujols | Chief Technology Officer | $591,360.00 | — | 56 | $0.00 | <0.01% |
Gregory Martini | Chief Financial Officer | $563,511.00 | — | 37 | $0.00 | <0.01% |
Marc Grasso | Strategic Advisor | $563,511.00 | — | 53 | $65,000.00 | 0.15% |
Christi L. Shaw | Executive Chairperson | $144,940.00 | — | 59 | $66,741.00 | 0.15% |
Dan Maziasz | Chief Business Officer | — | — | — | — | — |
Cara Bauer | Chief Human Resources Officer | — | — | — | — | — |
Jessica Serra | Head of Investor Relations | — | — | — | — | — |
Nadia Dac | Chief Commercial Officer | — | — | 56 | $300,000.00 | 0.69% |
Tracy Rossin | Senior Vice President of Corporate Affairs | — | — | 49 | — | — |
Tom Van Blarcom | Senior Vice President & Head of Research | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
2
$2.00M
Sells
1
$292,775.60
Net Sentiment
+$1.71M
Net buying
Most Active
SEIDENBERG BETH C
1 transactions
Analysis
Insiders reported 2 buys worth $2.00M and 1 sells worth $292,775.60 over the last 12 months. That adds up to net buying of $1.71M. SEIDENBERG BETH C was the most active insider with 1 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | N/A | N/A1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Peer companies in the same sector
Capricor Therapeutics, Inc.
NASDAQ:CAPR
$1.18B
Cabaletta Bio, Inc.
NASDAQ:CABA
$490.79M
Allogene Therapeutics, Inc.
NASDAQ:ALLO
$463.35M
Contineum Therapeutics, Inc. Class A Common Stock
NASDAQ:CTNM
$444.15M
Atea Pharmaceuticals, Inc.
NASDAQ:AVIR
$359.32M
Lexeo Therapeutics, Inc. Common Stock
NASDAQ:LXEO
$343.14M
Silence Therapeutics plc
NASDAQ:SLN
$316.00M
Lyell Immunopharma, Inc.
NASDAQ:LYEL
$315.01M
Editas Medicine, Inc.
NASDAQ:EDIT
$244.75M
Mereo BioPharma Group plc
MREO
$48.68M
Who manages KYTX?
Kyverna Therapeutics, Inc. (KYTX) lists 12 active executives. The top listed executive is Warner Biddle, Chief Executive Officer & Director.
Are KYTX insiders buying or selling?
Recent insider activity shows net buying of $52.74M.
Explore More
Continue the stock analysis
Jump to another research area for this company.